WeRide, CRISPR And GeneDx Are Amongst Prime 10 Mid-Cap Gainers Final Week (Feb 10-Feb 14): Are The Others In Your Portfolio? – GeneDx Hldgs (NASDAQ:WGS), CRISPR Therapeutics (NASDAQ:CRSP), WeRide (NASDAQ:WRD)

These ten mid-cap shares have been the very best performers within the final week. Are they in your portfolio?

WeRide Inc. WRD shares rocketed 97.62% after NVIDIA Company NVDA disclosed a stake of 1.74 million shares in a 13F submitting.
GDS Holdings Restricted GDS inventory escalated 43.45%, most likely after President Trump had reportedly postponed tariffs on packages beneath $800 from China. Moreover, optimism in the direction of China’s DeepSeek AI mannequin has additionally lifted shares lately.
SpringWorks Therapeutics, Inc. SWTX shares jumped 42.58% after asserting Merck KGaA MKGAF MKKGY is in superior discussions to amass the corporate.
Recursion Prescribed drugs, Inc. RXRX shares elevated 40.59%.
Sable Offshore Corp. SOC inventory upped 39.09%.
GeneDx Holdings Corp. WGS shares rose 28.23% after the corporate introduced UltraRapid Entire Genome Sequencing, which is able to ship actionable outcomes inside 48 hours.
VNET Group, Inc. VNET inventory upped 28.22%, most likely amid a potential rebound after falling final week as a consequence of AI competitors considerations associated to China’s DeepSeek AI mannequin.
Insperity, Inc. NSP inventory elevated 25.99% after the corporate reported better-than-expected fourth-quarter outcomes.
CRISPR Therapeutics AG CRSP inventory grew 25.21% after the corporate reported better-than-expected fourth-quarter monetary outcomes. A number of analysts raised the worth forecast on the inventory.
Axsome Therapeutics, Inc. AXSM inventory grew 24.01% after the corporate reached a settlement settlement with Teva Pharmaceutical TEVA, resolving all patent litigation associated to its Auvelity product. A number of analysts raised the worth forecast on the inventory.